Zhi-Yong Li

Dr. Zhi-Yong Li


Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 August 2015 in Diabetes
Verified
Journal Article
Open access
PDF file
ZLZhi-Yong Li
Zhi-Yong Li
JSJie Song
Jie Song
SZSi-Li Zheng
Si-Li Zheng
MFMao-Bing Fan
Mao-Bing Fan
YGYun-Feng Guan
Yun-Feng Guan
CMChao-Yu Miao
Chao-Yu Miao
Adipokines play important roles in metabolic homeostasis and disease. We have recently identified a novel adipokine Metrnl, also known as Subfatin, for its high expression in subcutaneous fat. Here, we demonstrate a prodifferentiation action of Metrnl in white adipocytes. Adipocyte-specific knockout of Metrnl exacerbates insulin resistance induced by high-fat diet (HFD), whereas adipocyte-specific transgenic overexpression of Metrnl prevents insulin resistance induced by HFD or leptin deletion. Body weight and adipose content are not changed by adipocyte Metrnl. Consistently, no correlation is found between serum Metrnl level and BMI in humans. Metrnl promotes white adipocyte differentiation, expandability, and lipid metabolism and inhibits adipose inflammation to form functional fat, which contributes to its activity against insulin resistance. The insulin sensitization of Metrnl is blocked by PPARγ inhibitors or knockdown. However, Metrnl does not drive white adipose browning. Acute intravenous injection of recombinant Metrnl has no hypoglycemic effect, and 1-week intravenous administration of Metrnl is unable to rescue insulin resistance exacerbated by adipocyte Metrnl deficiency. Our results suggest adipocyte Metrnl controls insulin sensitivity at least via its local autocrine/paracrine action through the PPARγ pathway. Adipocyte Metrnl is an inherent insulin sensitizer and may become a therapeutic target for insulin resistance.

10 January 2012 in British Journal of Pharmacology
Verified
Journal Article
Closed access
PDF file
CMChao-Yu Miao
Chao-Yu Miao
ZLZhi-Yong Li
Zhi-Yong Li

7 January 2014 in CNS Neuroscience & Therapeutics
Verified
Journal Article
Closed access
PDF file
ZLZhi-Yong Li
Zhi-Yong Li
SZSi‐Li Zheng
Si‐Li Zheng
PWPei Wang
Pei Wang
TXTian‐Ying Xu
Tian‐Ying Xu
YGYun‐Feng Guan
Yun‐Feng Guan
CMChao-Yu Miao
Chao-Yu Miao

30 September 2020 in Acta Pharmacologica Sinica
Verified
Journal Article
Closed access
PDF file
ZMZhu-Wei Miao
Zhu-Wei Miao
WHWen-Jun Hu
Wen-Jun Hu
ZLZhi-Yong Li
Zhi-Yong Li
CMChao-Yu Miao
Chao-Yu Miao

27 November 2011 in Clinical and Experimental Pharmacology and Physiology
Verified
Journal Article
Closed access
PDF file
ZLZhi-Yong Li
Zhi-Yong Li
PWPei Wang
Pei Wang
CMChao-Yu Miao
Chao-Yu Miao

7 April 2020 in Acta Pharmacologica Sinica
Verified
Journal Article
Closed access
PDF file
QQQi Qi
Qi Qi
WHWen-Jun Hu
Wen-Jun Hu
SZSi-Li Zheng
Si-Li Zheng
SZSai-Long Zhang
Sai-Long Zhang
YLYing-Ying Le
Ying-Ying Le
CMChao-Yu Miao
Chao-Yu Miao